These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 9458322

  • 1. The incidence of hepatocellular carcinoma in patients with chronic hepatitis C after interferon treatment.
    Miyajima I, Sata M, Kumashiro R, Uchimura Y, Ide T, Suzuki H, Tanikawa K.
    Oncol Rep; 1998; 5(1):201-4. PubMed ID: 9458322
    [Abstract] [Full Text] [Related]

  • 2. Effect of the dose and duration of interferon-alpha therapy on the incidence of hepatocellular carcinoma in noncirrhotic patients with a nonsustained response to interferon for chronic hepatitis C.
    Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Hayashi K, Honda T.
    Oncology; 2001; 61(2):134-42. PubMed ID: 11528252
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy.
    Oze T, Hiramatsu N, Yakushijin T, Miyazaki M, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Fukui H, Inui Y, Hijioka T, Inada M, Katayama K, Tamura S, Yoshihara H, Inoue A, Imai Y, Hayashi E, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hamasaki T, Hayashi N, Takehara T, Osaka Liver Forum.
    Clin Gastroenterol Hepatol; 2014 Jul; 12(7):1186-95. PubMed ID: 24321207
    [Abstract] [Full Text] [Related]

  • 5. Long-term responders without eradication of hepatitis C virus after interferon therapy: characterization of clinical profiles and incidence of hepatocellular carcinoma.
    Yabuuchi I, Imai Y, Kawata S, Tamura S, Noda S, Inada M, Maeda Y, Shirai Y, Fukuzaki T, Kaji I, Ishikawa H, Matsuda Y, Nishikawa M, Seki K, Matsuzawa Y.
    Liver; 2000 Jul; 20(4):290-5. PubMed ID: 10959807
    [Abstract] [Full Text] [Related]

  • 6. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
    Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Koyama R, Hosaka T, Sezaki H, Kobayashi M, Kumada H.
    Intervirology; 2007 Jul; 50(1):16-23. PubMed ID: 17164553
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy.
    Hung CH, Lee CM, Wang JH, Hu TH, Chen CH, Lin CY, Lu SN.
    Int J Cancer; 2011 May 15; 128(10):2344-52. PubMed ID: 20669224
    [Abstract] [Full Text] [Related]

  • 9. Prediction of efficacy of interferon treatment of chronic hepatitis C and occurrence of HCC after interferon treatment by a new classification.
    Kim KI, Sasase N, Taniguchi M, Mita K, Kim SR, Tanaka K, Hayashi Y.
    Intervirology; 2005 May 15; 48(1):52-8. PubMed ID: 15785090
    [Abstract] [Full Text] [Related]

  • 10. A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development.
    Kashiwagi K, Furusyo N, Kubo N, Nakashima H, Nomura H, Kashiwagi S, Hayashi J.
    J Infect Chemother; 2003 Dec 15; 9(4):333-40. PubMed ID: 14691655
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.
    Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kobayashi M, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kawamura Y, Kobayashi M, Kumada H.
    J Med Virol; 2007 Oct 15; 79(10):1485-90. PubMed ID: 17705189
    [Abstract] [Full Text] [Related]

  • 13. Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection.
    Arase Y, Ikeda K, Tsubota A, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Hosaka T, Sezaki H, Kobayashi M, Kumada H.
    Intervirology; 2004 Oct 15; 47(6):355-61. PubMed ID: 15564748
    [Abstract] [Full Text] [Related]

  • 14. Effect of interferon on incidence of hepatocellular carcinoma in patients with chronic hepatitis C.
    Soga K, Shibasaki K, Aoyagi Y.
    Hepatogastroenterology; 2005 Oct 15; 52(64):1154-8. PubMed ID: 16001651
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis.
    Aizawa Y, Shibamoto Y, Takagi I, Zeniya M, Toda G.
    Cancer; 2000 Jul 01; 89(1):53-9. PubMed ID: 10897000
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders.
    Imai Y, Tamura S, Tanaka H, Hiramatsu N, Kiso S, Doi Y, Inada M, Nagase T, Kitada T, Imanaka K, Fukuda K, Takehara T, Kasahara A, Hayashi N.
    J Viral Hepat; 2010 Mar 01; 17(3):185-91. PubMed ID: 19709362
    [Abstract] [Full Text] [Related]

  • 20. Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma.
    Takeyasu M, Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.
    J Med Virol; 2012 Aug 01; 84(8):1199-207. PubMed ID: 22711347
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.